
Miguel O'Ryan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6188570/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis. New England Journal of Medicine, 2006, 354, 11-22.	27.0	1,677
2	Norovirus Illness Is a Global Problem: Emergence and Spread of Norovirus GII.4 Variants, 2001–2007. Journal of Infectious Diseases, 2009, 200, 802-812.	4.0	596
3	Rotavirus infection. Nature Reviews Disease Primers, 2017, 3, 17083.	30.5	419
4	Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet, The, 2008, 371, 1181-1189.	13.7	365
5	Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet, The, 2012, 379, 617-624.	13.7	221
6	Variability of Human Milk Neutral Oligosaccharides in a Diverse Population. Journal of Pediatric Gastroenterology and Nutrition, 2000, 30, 181-192.	1.8	207
7	Prospective, Multicenter Evaluation of Risk Factors Associated With Invasive Bacterial Infection in Children With Cancer, Neutropenia, and Fever. Journal of Clinical Oncology, 2001, 19, 3415-3421.	1.6	203
8	A millennium update on pediatric diarrheal illness in the developing world. Seminars in Pediatric Infectious Diseases, 2005, 16, 125-136.	1.7	202
9	Prospective Evaluation of a Model of Prediction of Invasive Bacterial Infection Risk among Children with Cancer, Fever, and Neutropenia. Clinical Infectious Diseases, 2002, 35, 678-683.	5.8	137
10	A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program. Drugs, 2014, 74, 15-30.	10.9	125
11	Acute Diarrhea in West African Children: Diverse Enteric Viruses and a Novel Parvovirus Genus. Journal of Virology, 2012, 86, 11024-11030.	3.4	120
12	Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines. Frontiers in Immunology, 2019, 10, 1344.	4.8	105
13	Early Hospital Discharge Followed by Outpatient Management Versus Continued Hospitalization of Children With Cancer, Fever, and Neutropenia at Low Risk for Invasive Bacterial Infection. Journal of Clinical Oncology, 2004, 22, 3784-3789.	1.6	91
14	Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence in Blood in a Large School Community Subject to a Coronavirus Disease 2019 Outbreak: A Cross-sectional Study. Clinical Infectious Diseases, 2021, 73, e458-e465.	5.8	87
15	Prevalence of Astrovirus Infection among Chilean Children with Acute Gastroenteritis. Journal of Clinical Microbiology, 1998, 36, 3691-3693.	3.9	85
16	Rotavirus-associated medical visits and hospitalizations in South America: a prospective study at three large sentinel hospitals. Pediatric Infectious Disease Journal, 2001, 20, 685-693.	2.0	81
17	Rotarixâ,,¢ (RIX4414): an oral human rotavirus vaccine. Expert Review of Vaccines, 2007, 6, 11-19.	4.4	78
18	Review: Prevalence and dynamics of <i>Helicobacter pylori</i> infection during childhood. Helicobacter, 2017, 22, e12399.	3.5	75

#	Article	IF	CITATIONS
19	Persistence of antibodies in adolescents 18â^'24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Human Vaccines and Immunotherapeutics, 2013, 9, 2304-2310.	3.3	69
20	Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement. Frontiers in Immunology, 2020, 11, 1282.	4.8	68
21	Predictors of Severe Sepsis Not Clinically Apparent During the First Twenty-Four Hours of Hospitalization in Children With Cancer, Neutropenia, and Fever. Pediatric Infectious Disease Journal, 2008, 27, 538-543.	2.0	67
22	Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infectious Diseases, The, 2015, 15, 1273-1282.	9.1	65
23	The Ever-Changing Landscape of Rotavirus Serotypes. Pediatric Infectious Disease Journal, 2009, 28, S60-S62.	2.0	61
24	Impact of the Novel Influenza A (H1N1) during the 2009 Autumnâ€Winter Season in a Large Hospital Setting in Santiago, Chile. Clinical Infectious Diseases, 2010, 50, 860-868.	5.8	61
25	Two year review of intestinal intussusception in six large public hospitals of Santiago, Chile. Pediatric Infectious Disease Journal, 2003, 22, 717-721.	2.0	60
26	Update on Rotarixâ"¢: an oral human rotavirus vaccine. Expert Review of Vaccines, 2009, 8, 1627-1641.	4.4	59
27	Risk Factors Associated With Invasive Fungal Disease in Children With Cancer and Febrile Neutropenia. Pediatric Infectious Disease Journal, 2010, 29, 816-821.	2.0	58
28	Symptomatic and Asymptomatic Rotavirus and Norovirus Infections During Infancy in a Chilean Birth Cohort. Pediatric Infectious Disease Journal, 2009, 28, 879-884.	2.0	56
29	Admission Clinical and Laboratory Factors Associated With Death in Children With Cancer During a Febrile Neutropenic Episode. Pediatric Infectious Disease Journal, 2007, 26, 794-798.	2.0	55
30	Human Caliciviruses Are a Significant Pathogen of Acute Sporadic Diarrhea in Children of Santiago, Chile. Journal of Infectious Diseases, 2000, 182, 1519-1522.	4.0	51
31	The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations. Vaccine, 2015, 33, 6529-6536.	3.8	49
32	Cefepime in the empiric treatment of meningitis in children. Pediatric Infectious Disease Journal, 2001, 20, 356-361.	2.0	47
33	Seroprevalence of Norwalk Virus and Mexico Virus in Chilean Individuals: Assessment of Independent Risk Factors for Antibody Acquisition. Clinical Infectious Diseases, 1998, 27, 789-795.	5.8	45
34	Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for <i>Shigella</i> , <i>Salmonella,</i> enterotoxigenic <i>E. coli</i> (ETEC) enterohemorragic <i>E. coli</i> (EHEC) and <i>Campylobacter jejuni</i> . Human Vaccines and Immunotherapeutics, 2015, 11, 601-619.	3.3	45
35	Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines. Human Vaccines and Immunotherapeutics, 2018, 14, 1042-1057.	3.3	44
36	Impact of Rotavirus Infections on Outpatient Clinic Visits in Chile. Pediatric Infectious Disease Journal, 2007, 26, 41-45.	2.0	42

#	Article	IF	CITATIONS
37	Persistent and Transient <i>Helicobacter pylori</i> Infections in Early Childhood. Clinical Infectious Diseases, 2015, 61, 211-218.	5.8	41
38	Rotarix [®] : vaccine performance 6 years postlicensure. Expert Review of Vaccines, 2011, 10, 1645-1659.	4.4	40
39	Dynamics of Helicobacter pylori Detection in Stools During the First 5 Years of Life in Chile, a Rapidly Developing Country. Pediatric Infectious Disease Journal, 2013, 32, 99-103.	2.0	40
40	Novel Recombinant Norovirus Causing Outbreaks of Gastroenteritis in Santiago, Chile. Journal of Clinical Microbiology, 2006, 44, 2271-2275.	3.9	38
41	Prospective Characterization of Norovirus Compared With Rotavirus Acute Diarrhea Episodes in Chilean Children. Pediatric Infectious Disease Journal, 2010, 29, 855-859.	2.0	36
42	The fecal virome of South and Central American children with diarrhea includes small circular DNA viral genomes of unknown origin. Archives of Virology, 2016, 161, 959-966.	2.1	36
43	Norovirus in Latin America. Pediatric Infectious Disease Journal, 2017, 36, 127-134.	2.0	35
44	Effect of Maternal Rotavirus Immunization on Milk and Serum Antibody Titers. Journal of Infectious Diseases, 1995, 172, 723-728.	4.0	33
45	Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. Vaccine, 2019, 37, 1209-1218.	3.8	33
46	Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and <i>Vibrio cholerae</i> . Human Vaccines and Immunotherapeutics, 2015, 11, 584-600.	3.3	32
47	Acquisition of serum isotype-specific and G type-specific antirotavirus antibodies among children in day care centers. Pediatric Infectious Disease Journal, 1994, 13, 890-895.	2.0	31
48	New rotavirus vaccines: Renewed optimism. Journal of Pediatrics, 2006, 149, 448-451.	1.8	28
49	Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults. Vaccine, 2015, 33, 4437-4445.	3.8	28
50	Management of acute infectious diarrhea for children living in resource-limited settings. Expert Review of Anti-Infective Therapy, 2014, 12, 621-632.	4.4	27
51	Rotavirus Serum IgA Immune Response in Children Receiving Rotarix Coadministered With bOPV or IPV. Pediatric Infectious Disease Journal, 2016, 35, 1137-1139.	2.0	27
52	ACUTE GASTROENTERITIS IN LATIN AMERICA. Infectious Disease Clinics of North America, 1994, 8, 77-106.	5.1	27
53	Distinctive Gut Microbiota Is Associated with Diarrheagenic Escherichia coli Infections in Chilean Children. Frontiers in Cellular and Infection Microbiology, 2017, 7, 424.	3.9	26
54	Norovirus and Rotavirus Disease Severity in Children: Systematic Review and Meta-analysis. Pediatric Infectious Disease Journal, 2018, 37, 501-505.	2.0	26

#	Article	IF	CITATIONS
55	Diagnosis of Bacteremia in Febrile Neutropenic Episodes in Children With Cancer. Pediatric Infectious Disease Journal, 2011, 30, 957-961.	2.0	25
56	Prospective Validation of a Risk Prediction Model for Severe Sepsis in Children With Cancer and High-risk Febrile Neutropenia. Pediatric Infectious Disease Journal, 2013, 32, 1318-1323.	2.0	22
57	Gastric Damage and Cancer-Associated Biomarkers in Helicobacter pylori-Infected Children. Frontiers in Microbiology, 2020, 11, 90.	3.5	22
58	Differential Time to Positivity and Quantitative Cultures for Noninvasive Diagnosis of Catheter-Related Blood Stream Infection in Children. Pediatric Infectious Disease Journal, 2008, 27, 681-685.	2.0	20
59	Rotavirus vaccines for the developing world. Current Opinion in Infectious Diseases, 2009, 22, 483-489.	3.1	19
60	An update on management of severe acute infectious gastroenteritis in children. Expert Review of Anti-Infective Therapy, 2010, 8, 671-682.	4.4	19
61	Norovirus: Facts and Reflections from Past, Present, and Future. Viruses, 2021, 13, 2399.	3.3	19
62	Human rotavirus vaccine (<i>Rotarix</i>): focus on effectiveness and impact 6 years after first introduction in Africa. Expert Review of Vaccines, 2015, 14, 1099-1112.	4.4	18
63	Caliciviruses and Foodborne Gastroenteritis, Chile. Emerging Infectious Diseases, 2005, 11, 1134-1137.	4.3	17
64	Development and validation of a microarray for the confirmation and typing of norovirus RT-PCR products. Journal of Virological Methods, 2011, 173, 233-250.	2.1	16
65	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). Frontiers in Medicine, 2020, 7, 572485.	2.6	15
66	Rotavirus Vaccines: a story of success with challenges ahead. F1000Research, 2017, 6, 1517.	1.6	15
67	Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame. Clinical Infectious Diseases, 2018, 67, S57-S65.	5.8	14
68	Molecular epidemiology of human rotaviruses in Santiago, Chile. Pediatric Infectious Disease Journal, 1997, 16, 305-311.	2.0	14
69	Genomic and antigenic variation among rotavirus strains circulating in a large city of Argentina. Journal of Medical Virology, 2000, 61, 504-509.	5.0	13
70	Helicobacter pylori cagA+ Is Associated with Milder Duodenal Histological Changes in Chilean Celiac Patients. Frontiers in Cellular and Infection Microbiology, 2017, 7, 376.	3.9	13
71	Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules. Vaccine, 2017, 35, 7283-7291.	3.8	11
72	The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries. Viruses, 2021, 13, 2391.	3.3	11

#	Article	IF	CITATIONS
73	Norovirus compared to other relevant etiologies of acute gastroenteritis among families from a semirural county in Chile. International Journal of Infectious Diseases, 2020, 101, 353-360.	3.3	9
74	A cross sectional study found differential risks for COVID-19 seropositivity amongst health care professionals in Chile. Journal of Clinical Epidemiology, 2022, 144, 72-83.	5.0	9
75	Clinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience. Trials in Vaccinology, 2012, 1, 10-20.	1.2	8
76	Predominance of Rotavirus G8P[8] in a City in Chile, a Country Without Rotavirus Vaccination. Journal of Pediatrics, 2019, 204, 298-300.e1.	1.8	8
77	Parenteral protein-based rotavirus vaccine. Lancet Infectious Diseases, The, 2017, 17, 786-787.	9.1	7
78	Enteric viruses in wastewaters: an interesting approach to evaluate the potential impact of rotavirus vaccination on viral circulation. Expert Review of Vaccines, 2012, 11, 419-422.	4.4	6
79	Detection ofHelicobacter pyloriby Real-Time PCR for 16s rRNA in Stools of NonInfected Healthy Children, Using ELISA Antigen Stool Test as the Gold Standard. Helicobacter, 2016, 21, 606-612.	3.5	6
80	The burden of norovirus disease in children: a multi-country study in Chile, Brazil, Thailand and the Philippines. International Journal of Infectious Diseases, 2021, 109, 77-84.	3.3	6
81	Microorganisms Responsible for Neonatal Diarrhea. , 2011, , 359-418.		5
82	Parent reported outcomes to measure satisfaction, acceptability, and daily life impact after vaccination with whole-cell and acellular pertussis vaccine in Chile. Vaccine, 2020, 38, 6704-6713.	3.8	5
83	Effect of <i>Helicobacter pylori</i> eradication therapy on clinical and laboratory biomarkers associated with gastric damage in healthy schoolâ€aged children: A randomized nonâ€blinded trial. Helicobacter, 2021, 26, e12853.	3.5	5
84	Can we defeat meningococcal disease in low and middle income countries?. Vaccine, 2012, 30, B63-B66.	3.8	4
85	Helicobacter pylori, clinical, laboratory, and noninvasive biomarkers suggestive of gastric damage in healthy school-aged children: A case-control study. International Journal of Infectious Diseases, 2021, 103, 423-430.	3.3	4
86	Indications for <i>Helicobacter pylori</i> Eradication. Journal of Pediatric Gastroenterology and Nutrition, 2018, 67, e86-e87.	1.8	3
87	SARS-COV-2 IgG positivity in vaccinated and non-vaccinated Chilean children: a national cross-sectional study in schools. International Journal of Infectious Diseases, 2022, 121, 89-91.	3.3	3
88	Rotavirus vaccines roll-out in resource-deprived regions. Lancet Infectious Diseases, The, 2015, 15, 368-370.	9.1	1
89	Safeguarding vaccine production and supply strategies for polio eradication endgame. The Lancet Regional Health - Western Pacific, 2021, 11, 100159.	2.9	1
90	Therapy of acute purulent otitis media with dibenzylethylenediamine dipenicillin G Journal of Pediatrics, 2004, 144, 269.	1.8	0

#	Article	IF	CITATIONS
91	Meningococcal infections: With particular reference to fulminant meningococcemia (Waterhouse-Friderichsen Syndrome) treated with cortisone and norepinephrine. Journal of Pediatrics, 2004, 145, 234.	1.8	0
92	3 Determination of Rotavirus′ Serotypes in Children Younger than 36 Months of Age with Acute Gastroentheritis and Deshydration in the Concepción - Talcahuano Area, Chile. Pediatric Research, 2005, 57, 920-920.	2.3	0
93	Rotavirus vaccine for developing countries – Authors' reply. Lancet, The, 2008, 372, 445.	13.7	0
94	Miguel O'Ryan Gallardo, nuevo miembro en la Academia de Medicina de Chile. Revista Chilena De Infectologia, 2012, 29, 487-491.	0.1	0